Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid
about
Considerations for accurate gene expression measurement by reverse transcription quantitative PCR when analysing clinical samplesIncreased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphomaOut of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaBCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphomaTesting for HER2 in Breast Cancer: A Continuing Evolution.HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancerHybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation studyLaminin 332 expression in breast carcinomaA gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsHER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort.Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.HER2 assessment by silver in situ hybridization: where are we now?Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival.The assessment of HER2 status in breast cancer: the past, the present, and the future.Kappa and lambda light chain mRNA in situ hybridization compared to flow cytometry and immunohistochemistry in B cell lymphomas.Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection.Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?Fully automated dual-color dual-hapten silver in situ hybridization staining for MYC amplification: a diagnostic tool for discriminating secondary angiosarcoma.Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas.Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.Development of an easy method to test for HER2 in breast cancer using dual-color in situ hybridization.Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation.HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.
P2860
Q26863503-74DE1DB5-3133-40C9-A1E2-C2211C16A474Q33800442-FEB5DD35-C281-4D44-95CA-D71AA6EB3AD1Q34064466-C6B2AEBF-C94E-41B8-9EFA-0F1072BA47F0Q34339662-F4B0575A-C5B6-4079-BA9C-CCC94389A7ADQ34424285-67B7AF62-2CC0-445C-A5C6-14866C7C36F7Q34638138-13E8608B-F71B-4DA4-A8BD-C11C6F05840AQ35195417-3BD41205-BD5C-470D-8966-6943D075F0F3Q35284728-310DE268-A59E-460A-A247-D9F256FEF0F6Q35825928-CDA48F7D-AD02-4C78-817B-07A7DD2C762AQ36367606-269235D7-43C6-46BE-8FE7-1F5D77767201Q36849324-137E192B-4F81-43A8-93C1-2AD023406060Q36950483-4AD67DCD-8913-471B-8637-B2BB08A647E1Q37075632-BE2FAB4B-E729-4111-9F06-13AF5B5F065FQ37595263-5148A487-535F-4146-B1EA-D9D83150F2BEQ37677852-107E97DF-8905-4991-9FA1-963B6A425892Q38314355-CCA80725-EB95-4760-A3F5-355E26CD727FQ38412375-227006F7-09AE-46D1-A7D2-4476A3C7CD8DQ38612634-7E40FB1B-0C16-47B4-81C2-7E325D2B0E98Q38726662-618448B1-CEBE-44AF-BC1C-B0B3CA443D0AQ38802932-8E5CB0AC-C01A-46AE-9E65-E5F870FCE523Q42983340-F1642F28-B5D1-44A7-BBAB-D5971D80D397Q43712233-A0C0EE72-8F12-4F0B-9038-C8FB86ACAED3Q44468300-77255054-8720-4D37-BF32-CCDBCE740968Q45991665-446FB8A0-3960-4153-A8EA-AB79D4C60953Q46565660-EBAC3E52-1BD9-40D1-A2F1-B71E0FBAA9C1Q47254055-F9163FE3-C533-4997-8DB8-E9A1E0E295CCQ48155048-2D51CD2A-44B0-4096-BF5F-E53CC0532646Q50482423-58503E6E-DD43-4744-A708-67BE831C81F8Q50893707-32D66906-1737-479B-BDA4-051814A1129FQ50911078-D99A3684-E754-4120-99AD-2EE823A11DBBQ50992951-E5A41787-B7A8-4EFF-8785-37BAD49D113BQ51707520-ED641732-78DB-4E98-87A4-FE2E85B62979Q53280611-99BD7F47-0338-47DB-96E0-037B24BCF447Q54197932-2CFEB4DB-0606-4E23-A83D-F3AAD5C8BCFFQ54353219-4591F4BA-ED6D-485C-9D3E-AA56B06A93F7Q54356831-813C7E7F-4BC9-4F41-8EE0-71DCA2D168EBQ54518974-D465C704-64DB-40F3-A891-8BCED637EF75Q54594739-F4E203D5-327F-4B84-BD75-F0DA2F1E8392Q54594744-0DF13F00-FDE3-4864-B8FE-7131877E4306
P2860
Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Development of automated brigh ...... R2 fluorescence in situ hybrid
@ast
Development of automated brigh ...... R2 fluorescence in situ hybrid
@en
type
label
Development of automated brigh ...... R2 fluorescence in situ hybrid
@ast
Development of automated brigh ...... R2 fluorescence in situ hybrid
@en
prefLabel
Development of automated brigh ...... R2 fluorescence in situ hybrid
@ast
Development of automated brigh ...... R2 fluorescence in situ hybrid
@en
P2093
P2860
P356
P1433
P1476
Development of automated brigh ...... R2 fluorescence in situ hybrid
@en
P2093
Adrian E Murillo
Beatrice Hauss-Wegrzyniak
Fabien Gaire
Frederique Penault-Llorca
Hiroaki Nitta
James Pettay
Margaret Loftus
Masafumi Kurosumi
P2860
P2888
P356
10.1186/1746-1596-3-41
P577
2008-10-22T00:00:00Z
P5875
P6179
1036746612